Clinical review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
CADTH
Record ID 32014000800
English
Authors' recommendations:
Two multi-centre, randomized, parallel group, double-masked, placebo-controlled studies comparing a single 125 mcg intravitreal injection of ocriplasmin with a placebo injection for the treatment of VMA were reviewed. Overall, treatment with ocriplasmin was superior to placebo for the resolution of VMA and total PVD. Although there was a greater overall incidence of AEs for patients treated with ocriplasmin compared with placebo, many events were transient and were possibly related to the procedure instead of the drug itself. There is uncertainty regarding the efficacy of ocriplasmin for the treatment of FTMHs, avoidance of vitrectomy, and improvement in BCVA. Moreover, no data were available on whether ocriplasmin prevents VMA-related vision loss or blindness, which are key outcomes according to patient groups.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/clinical/SR0337_Jetrea_CL_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Peptide Fragments
- Eye Diseases
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.